These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31339384)

  • 1. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.
    Cohen K; Maartens G
    Expert Opin Drug Saf; 2019 Oct; 18(10):875-882. PubMed ID: 31339384
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
    Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
    Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
    Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.
    Pontali E; Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Migliori GB
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146605
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
    Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
    BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline. More data needed on this dangerous antitubercular drug.
    Prescrire Int; 2014 Oct; 23(153):232-4. PubMed ID: 25964964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
    Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
    Holmgaard FB; Guglielmetti L; Lillebaek T; Andersen ÅB; Wejse C; Dahl VN
    Clin Infect Dis; 2023 Apr; 76(7):1328-1337. PubMed ID: 36331978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
    Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439
    [No Abstract]   [Full Text] [Related]  

  • 20. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.
    Patel H; Pawara R; Pawara K; Ahmed F; Shirkhedkar A; Surana S
    Tuberculosis (Edinb); 2019 Jul; 117():79-84. PubMed ID: 31378273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.